Healthcare / Medical Instruments & SuppliesTokyo
$1828.00
+10.00 (+0.55%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.5B · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$65.1B
P/E
13.4x
↓EV/EBITDA
7.5x
↓ROE
10.1%
↑Gross Margin
59.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.2%
FCF CAGR
-7.3%
FCF margin
5.5%
FCF / Net income
0.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $38.70B · net income $4.32B · FCF $2.13B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $38.70B | $38.70B | $35.08B | $31.68B | $28.14B |
| Net Income | $4.32B | $4.32B | $3.65B | $3.13B | $2.55B |
| EBITDA | $7.23B | $7.23B | $6.47B | $5.40B | $4.52B |
| EPS | 121.09 | 121.09 | 102.62 | 87.56 | 71.17 |
| Gross Margin | 59.4% | 59.4% | 59.8% | 59.0% | 57.5% |
| Operating Margin | 13.9% | 13.9% | 13.4% | 12.1% | 11.4% |
| Net Margin | 11.2% | 11.2% | 10.4% | 9.9% | 9.0% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.01 | 0.03 | 0.04 |
| Current Ratio | 4.74 | 4.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.13B | $2.13B | $1.38B | $1.54B | $2.67B |
| Returns | |||||
| ROE | 10.1% | 10.1% | 8.8% | 8.8% | 7.7% |
| Valuation | |||||
| P/E | 13.35 | 13.35 | 14.28 | 11.37 | 11.30 |
| EV/EBITDA | 7.54 | 7.54 | 6.60 | 5.05 | 4.68 |
| P/B | 1.53 | 1.53 | 1.26 | 1.01 | 0.87 |
| Growth & Yield | |||||
| Revenue Growth | 10.3% | 10.3% | 10.7% | 12.6% | — |
| EPS Growth | 18.0% | 18.0% | 17.2% | 23.0% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
10.2%
EPS terminal req.
$162.20
Spread vs growth
7.8%
5Y implied EPS CAGR
10.1%
EPS terminal req.
$196.27
Spread vs growth
7.9%
10Y implied EPS CAGR
10.1%
EPS terminal req.
$316.09
Spread vs growth
7.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.0%
Start / end P/E
21.2x → 15.1x
EPS bridge
102.62 → 121.09
Residual
-5.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.